Does cannabis interact with statins?

Yes. CBD and THC inhibit CYP3A4, the liver enzyme responsible for metabolizing several commonly prescribed statins — including atorvastatin (Lipitor), simvastatin (Zocor), and lovastatin. When CYP3A4 is inhibited, statin plasma levels rise, increasing the risk of statin-related muscle side effects (myopathy). The interaction risk varies significantly by which statin is prescribed: rosuvastatin and pravastatin use different metabolic pathways and carry substantially lower interaction risk.

Can I take CBD oil while on atorvastatin?

CBD inhibits CYP3A4, which is the primary metabolic pathway for atorvastatin (Lipitor). This means CBD use can raise atorvastatin plasma concentrations beyond the prescribed dose level, increasing the risk of myopathy (muscle pain and weakness). Whether to use both together is a prescriber decision that should include awareness of CBD dose, atorvastatin dose, and individual risk factors. Patients should disclose CBD use to the prescriber managing their statin therapy.

Which statins are safest to use with cannabis?

Rosuvastatin (Crestor) and pravastatin (Pravachol) are the statins least sensitive to CYP3A4 inhibition. Rosuvastatin is primarily transported by OATP1B1 and minimally metabolized by CYP enzymes. Pravastatin undergoes minimal CYP-mediated metabolism. If a prescriber is selecting a statin for a patient who uses cannabis regularly, these two carry lower pharmacokinetic interaction concern than atorvastatin, simvastatin, or lovastatin.

Cannabis & Statins Interaction: CYP3A4, Myopathy Risk, and Statin-by-Statin Breakdown

The Mechanism: CYP3A4 Competition

Clinical Pharmacology

CYP3A4 Is the Most Important Drug-Metabolizing Enzyme

CYP3A4 is responsible for metabolizing an estimated 30–50% of all clinically used medications. It is the dominant clearance pathway for many statins — particularly atorvastatin, simvastatin, and lovastatin. When CYP3A4 activity is reduced (inhibited), these drugs are cleared more slowly and plasma concentrations rise. NIH NCCIH

CBD and THC Inhibit CYP3A4

Both cannabidiol (CBD) and tetrahydrocannabinol (THC) are substrates and inhibitors of CYP3A4. CBD is the more potent inhibitor. This is documented in the FDA prescribing information for Epidiolex and in peer-reviewed pharmacokinetic research examining cannabinoids as drug-metabolizing enzyme modulators. FDA Epidiolex PI Stout & Cimino, 2014

Higher Statin Levels Raise Myopathy Risk

Statin-related adverse effects — muscle pain (myalgia), muscle weakness (myopathy), and in serious cases, muscle breakdown (rhabdomyolysis) — are concentration-dependent. The higher the statin plasma level, the greater the likelihood of muscle-related side effects. Factors that raise statin levels (including CYP3A4 inhibition by cannabis) shift patients toward higher risk on this dose-response curve. NIH MedlinePlus

Statin-by-Statin Risk Stratification

Which Statin Matters Most

Statin	Brand Names	Primary Metabolism	Cannabis Interaction Risk
Atorvastatin	Lipitor	Primarily CYP3A4	⚠️ Caution — most sensitive to CYP3A4 inhibition; most widely prescribed statin
Simvastatin	Zocor	Primarily CYP3A4	⚠️ Caution — already has strict grapefruit interaction warning; cannabis adds similar concern
Lovastatin	Altoprev, Mevacor	Primarily CYP3A4	⚠️ Caution — similar profile to simvastatin; CYP3A4 dependent
Fluvastatin	Lescol	Primarily CYP2C9	🔵 Moderate — CBD inhibits CYP2C9 as well; some interaction concern via different enzyme
Rosuvastatin	Crestor	Minimal CYP; primarily OATP1B1 transporter	✓ Lower Risk — minimal CYP3A4 metabolism; generally preferred in cannabis users
Pravastatin	Pravachol	Minimal CYP metabolism	✓ Lower Risk — undergoes minimal hepatic CYP metabolism; lower pharmacokinetic interaction concern
Pitavastatin	Livalo	Minimal CYP metabolism (some CYP2C9)	✓ Lower Risk — limited CYP-mediated clearance; lower interaction risk than CYP3A4-dependent statins

Recognizing Statin Myopathy

Clinical Warning Signs

Elevated statin levels from CYP3A4 inhibition may manifest as muscle-related side effects that can be mistaken for other conditions. Patients on CYP3A4-metabolized statins who use cannabis should be aware of these symptoms:

Myalgia (muscle pain or aching) — especially in large muscle groups (thighs, upper arms, lower back). Pain that is new, unexplained, or symmetric.
Muscle weakness — difficulty climbing stairs, rising from a chair, or lifting arms.
Muscle tenderness disproportionate to physical activity.
Dark or cola-colored urine — a potential sign of myoglobinuria from rhabdomyolysis, requiring immediate medical attention.
Fatigue accompanying muscle symptoms — may be early myopathy.

When to Contact Your Prescriber

If you develop unexplained muscle pain, weakness, or dark urine while on a statin and using cannabis, contact your prescriber promptly. Statin myopathy is manageable when caught early. Rhabdomyolysis — the serious end of this spectrum — requires prompt medical evaluation and in some cases hospitalization.

Dose and Frequency Considerations

Practical Context

The magnitude of the cannabis–statin interaction depends on several variables that affect CYP3A4 inhibition severity:

CBD Concentration in the Product

CBD is the more potent CYP3A4 inhibitor. Full-spectrum edibles and high-dose CBD oils carry more interaction risk than low-CBD, high-THC flower. Product labeling for CBD content matters.

Oral vs. Inhaled

Oral cannabis passes through the liver before reaching systemic circulation (first-pass metabolism), concentrating CBD and THC exposure at CYP enzymes. Inhaled cannabis bypasses this, reducing but not eliminating CYP3A4 interaction.

Frequency of Use

Daily cannabis use creates sustained CYP3A4 inhibition. Occasional use produces transient inhibition. Sustained inhibition carries more interaction risk for statin plasma level elevation.

Statin Dose

Patients on higher statin doses have less pharmacokinetic margin before plasma levels reach myopathy-risk territory. The interaction is potentially more clinically significant at higher statin doses.

Frequently Asked Questions

Common Queries

Can I take CBD oil while on Lipitor (atorvastatin)? ▼

CBD inhibits CYP3A4 — the primary metabolic enzyme for atorvastatin. This means CBD use can raise atorvastatin plasma concentrations, increasing myopathy risk. Whether to use both is a prescriber decision. If you currently use CBD and take atorvastatin, disclose this to your prescriber so they can assess your specific dose combination and monitor for muscle-related side effects. Do not start or significantly increase CBD use while on atorvastatin without this conversation.

Is it safer to use cannabis while on Crestor (rosuvastatin) than Lipitor? ▼

From a pharmacokinetic standpoint, yes — rosuvastatin (Crestor) carries substantially lower cannabis interaction risk than atorvastatin (Lipitor). Rosuvastatin is primarily eliminated via the OATP1B1 hepatic transporter and undergoes minimal CYP3A4 metabolism, so CBD and THC's CYP3A4 inhibition has far less effect on rosuvastatin plasma levels than on atorvastatin. If a prescriber is selecting a statin for a patient who uses cannabis regularly, rosuvastatin or pravastatin represent pharmacokinetically lower-risk options. This is a prescriber-guided decision, not an over-the-counter switch.

My pharmacist warned me about grapefruit and my statin. Is cannabis the same issue? ▼

The mechanism is the same. Grapefruit contains furanocoumarins that irreversibly inhibit intestinal CYP3A4. CBD inhibits CYP3A4 in the liver through a different mechanism but with overlapping clinical consequences — elevated statin plasma levels. If you have been counseled to avoid grapefruit with simvastatin or lovastatin because of CYP3A4 inhibition, CBD-containing cannabis products carry a similar interaction concern for the same biochemical reason. The potency and duration differ between grapefruit and CBD, but the direction of the effect is the same.

Does THC interact with statins differently than CBD? ▼

Both CBD and THC inhibit CYP3A4, but CBD is the more potent inhibitor. THC-dominant cannabis products (high THC, low CBD flower) carry lower pharmacokinetic interaction risk with CYP3A4-metabolized statins than high-CBD products like CBD oils or full-spectrum edibles with significant CBD content. However, THC itself is a CYP3A4 substrate — meaning the two compete for the same enzyme, which can still affect statin clearance. All cannabis use should be disclosed to the statin prescriber regardless of THC-to-CBD ratio.

👨‍⚕️ Clinical Reviewer

Sanford A. Orloff, RPh (ret.)

Registered Pharmacist · 40+ Years Clinical Experience · NPI: 1518289974
View credentials → · Verify NPI →

📚

Primary Sources

Stout SM, Cimino NM. "Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review." Drug Metabolism Reviews. 2014 Feb;46(1):86-95. PMID: 24160757.
https://doi.org/10.3109/03602532.2013.849268
FDA. Epidiolex (cannabidiol) Prescribing Information. NDA 210365. Section 7 and 12.3: CYP3A4 inhibition by CBD documented at therapeutic concentrations.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210365s006lbl.pdf
NIH National Center for Complementary and Integrative Health (NCCIH). "Cannabis (Marijuana) and Cannabinoids: What You Need To Know." Updated December 2021.
https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
NIH MedlinePlus. Atorvastatin; Simvastatin; Rosuvastatin — Drug Information. National Library of Medicine. Metabolism and drug interaction sections.
https://medlineplus.gov/druginformation.html